4.8 Review

Liver cirrhosis

期刊

LANCET
卷 371, 期 9615, 页码 838-851

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(08)60383-9

关键词

-

资金

  1. NCCIH NIH HHS [U01 AT003571-01, U01 AT003571, U01 AT003571-02] Funding Source: Medline
  2. NIAID NIH HHS [U19 AI066313-029001, U19 AI066313-049001, U19 AI066313-030003, U19 AI066313-020003, U19 AI066313-039001, U19 AI066313-010003, U19 AI066313-019001, U19 AI066313-040003] Funding Source: Medline
  3. NIDDK NIH HHS [R21 DK076873-01A1, 1 R21 DK076873-01A1] Funding Source: Medline
  4. PHS HHS [U19 A1 066313] Funding Source: Medline

向作者/读者索取更多资源

Cirrhosis is defined as the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury, which leads to portal hypertension and end-stage liver disease. Recent advances in the understanding of the natural history and pathophysiology of cirrhosis, and in treatment of its complications, have resulted in improved management, quality of life, and life expectancy of patients. Liver transplantation remains the only curative option for a selected group of patients, but pharmacological treatments that can halt progression to decompensated cirrhosis or even reverse cirrhosis are currently being developed. This Seminar focuses on the diagnosis, complications, and management of cirrhosis, and new clinical and scientific developments.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据